Loading...
Loading...
Innate Pharma SA
Innate Pharma SA. Spoken Alpha tracks IPHA's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks IPHA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IPHA.
curl https://api.spokenalpha.com/v1/companies/IPHA| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.56 | $3.56 | +28.2% | -5.3% | -6.9% |
| Q4 FY2026 | $4.89 | $3.54 | +38.0% | +1.7% | +1.6% |
| Q3 FY2026 | $4.93 | $3.65 | +35.0% | -1.0% | -3.3% |
| Q2 FY2026 | $5.29 | $3.71 | +42.5% | -4.1% | -7.1% |
| Q1 FY2025 | $4.84 | $3.69 | +31.2% | +6.0% | +8.1% |
| Q4 FY2025 | $4.90 | $3.70 | +32.5% | -2.4% | -1.1% |
| Q3 FY2025 | $5.00 | $3.71 | +34.9% | +3.7% | +5.4% |
| Q2 FY2025 | $4.73 | $3.63 | +30.4% | +0.4% | +0.4% |
| Q1 FY2024 | $5.40 | $3.85 | +40.2% | +4.2% | +2.3% |
| Q4 FY2024 | $4.96 | $3.88 | +27.8% | +2.5% | +4.3% |